Sandoz to settle US states' antitrust claims over generic drugs for $400m
MLex Summary: Sandoz reached a $400 million settlement with a coalition of 48 attorneys general to resolve claims that it conspired to artificially inflate generic drug prices and reduce competition. The...To view the full article, register now.
Already a subscriber? Click here to view full article